中文 | English
Return
Total: 6 , 1/1
Show Home Prev Next End page: GO
Author:(Chieh Yi KANG)

2.Treatment outcomes of patients with stage II pure endometrioid-type endometrial cancer: a Taiwanese Gynecologic Oncology Group (TGOG-2006) retrospective cohort study.

Hung Chun FU ; Jen Ruei CHEN ; Min Yu CHEN ; Keng Fu HSU ; Wen Fang CHENG ; An Jen CHIANG ; Yu Min KE ; Yu Chieh CHEN ; Yin Yi CHANG ; Chia Yen HUANG ; Chieh Yi KANG ; Yuan Yee KAN ; Sheng Mou HSIAO ; Ming Shyen YEN

Journal of Gynecologic Oncology 2018;29(5):e76-

3.Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.

Jeng Sen TSENG ; Tsung Ying YANG ; Kun Chieh CHEN ; Kuo Hsuan HSU ; Yen Hsiang HUANG ; Kang Yi SU ; Sung Liang YU ; Gee Chen CHANG

Cancer Research and Treatment 2018;50(4):1164-1174

4.Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Tzu-Yi LIN ; Eugene Yu-Chuan KANG ; Shih-Chieh SHAO ; Edward Chia-Cheng LAI ; Sunir J. GARG ; Kuan-Jen CHEN ; Je-Ho KANG ; Wei-Chi WU ; Chi-Chun LAI ; Yih-Shiou HWANG

Diabetes & Metabolism Journal 2023;47(3):394-404

5.The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.

Yen Hsiang HUANG ; Kuo Hsuan HSU ; Jeng Sen TSENG ; Kun Chieh CHEN ; Chia Hung HSU ; Kang Yi SU ; Jeremy J W CHEN ; Huei Wen CHEN ; Sung Liang YU ; Tsung Ying YANG ; Gee Chen CHANG

Cancer Research and Treatment 2018;50(4):1294-1303

6.The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

Yen-Hsiang HUANG ; Kuo-Hsuan HSU ; Chun-Shih CHIN ; Jeng-Sen TSENG ; Tsung-Ying YANG ; Kun-Chieh CHEN ; Kang-Yi SU ; Sung-Liang YU ; Jeremy J.W. CHEN ; Gee-Chen CHANG

Cancer Research and Treatment 2022;54(2):434-444

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 6 , 1/1 Show Home Prev Next End page: GO